ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 281 filers reported holding ROYALTY PHARMA PLC in Q2 2022. The put-call ratio across all filers is 0.10 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $114,264,692 | +1.9% | 4,210,195 | +15.4% | 0.02% | 0.0% |
| Q2 2023 | $112,110,502 | +35.1% | 3,647,056 | +58.3% | 0.02% | +27.8% |
| Q1 2023 | $82,989,520 | +71.9% | 2,303,345 | +88.6% | 0.02% | +63.6% |
| Q4 2022 | $48,272,059 | -12.7% | 1,221,459 | -11.3% | 0.01% | -15.4% |
| Q3 2022 | $55,316,000 | +33.4% | 1,376,705 | +39.6% | 0.01% | +44.4% |
| Q2 2022 | $41,473,000 | -28.4% | 986,527 | -33.7% | 0.01% | -25.0% |
| Q1 2022 | $57,958,000 | +11.4% | 1,487,630 | +13.9% | 0.01% | +20.0% |
| Q4 2021 | $52,025,000 | +60.4% | 1,305,520 | +45.5% | 0.01% | +42.9% |
| Q3 2021 | $32,432,000 | -23.3% | 897,403 | -13.1% | 0.01% | -30.0% |
| Q2 2021 | $42,306,000 | +147.3% | 1,032,101 | +163.2% | 0.01% | +150.0% |
| Q1 2021 | $17,107,000 | -35.2% | 392,170 | -25.7% | 0.00% | -42.9% |
| Q4 2020 | $26,414,000 | +256.9% | 527,760 | +200.0% | 0.01% | +250.0% |
| Q3 2020 | $7,400,000 | +401.4% | 175,903 | +478.6% | 0.00% | – |
| Q2 2020 | $1,476,000 | – | 30,403 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |